R&A PSYINS Announces Strategic Partnership with Nucleus to Provide the Psychedelic Industry Insurance Coverage
R&A PSYINS, an independent insurance broker that provides insurance to the psychedelic industry, announced a strategic partnership with
This landmark partnership was established to address a paramount issue facing psychedelic medicinal businesses. While more state legislators are pushing forward psychedelic policy reform – opening the door for more therapists and clinicians, retreats, and investors to enter the space – it is extremely difficult for psychedelic medicinal businesses to access insurance in this current hardened insurance market, leaving them exposed to a wide spectrum of risks.
Psychedelic therapies are in the highest risk pool for malpractice and other claims. Ketamine clinics, therapists and other practitioners need to understand, mitigate, and protect themselves from these perils. For companies that manufacture, test and distribute psychedelics for medicinal purposes, there are a host of additional risks, particularly if the goal is to go public. In response, R&A PSYINS developed a risk management program that offers specialty lines of business and medical malpractice insurance policies, including Professional Liability/Errors & Omissions, General Liability, Directors & Officers Liability, Product Liability, IP Defense/Enforcement, Cyber Defense/Data Breach and Workers’ Compensation coverage.
Nucleus, which is wholly owned by the venture capital firm, Iter Investments, is comprised of technology, data, and media assets intended to deliver intelligence, education, and opportunities to psychedelic industry stakeholders. The company’s acquisition of Psychedelic Invest and Neuly in 2022 was the foundation for its robust ecosystem. With its proprietary search technology, vast database, and suite of educational assets, Nucleus is helping to propel transformative health treatments forward.
“Both of our companies are at the forefront of the psychedelic medicinal movement,” said
This new partnership will benefit all stakeholders in Nucleus’ robust ecosystem by providing them access to psychedelic industry insurance that will ensure they are fully protected and in compliance with state and federal HIPPA regulations.
“We couldn’t be more excited to partner with a company like R&A PSYINS,” said
###
About R&A PSYINS
R&A PSYINS is a division of
+1 401-368-6655
courtney@s2sinsure.com
Visit us on social media:
LinkedIn


Aspire General Insurance Appoints Byron Storms as CEO and Chairman
MetLife Named One of America’s Most Just Companies
Advisor News
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
- Semi-retirement: helping clients balance flexibility with financial security
- The 6X Formula for leveraging content marketing with AI
- When a home becomes difficult to insure, the plan changes
More Advisor NewsAnnuity News
- Jackson Launches Direct-to-Consumer Annuity Offering
- Global Atlantic launches ForeIncome Flex
- Athene CEO criticizes offshore reinsurance, risk-taking by competitors
- DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
- John Hancock launches new fixed indexed annuity suite
More Annuity NewsHealth/Employee Benefits News
- Health Plans Expect Double-Digit Premium Increases Again in 2027
- Best’s Special Report: Rising Costs Could Offset AI-Driven Efficiency Gains at US Health Insurers
- Free Medicare counseling provided through LTADD
- Illinois consumers see higher prices and fewer choices for Obamacare health insurance
- COMPREHENSIVE REGULATIONS TO UNCOVER SUSPICIOUS HEALTHCARE (CRUSH) PROPOSED RULE (CMS-6098-P)
More Health/Employee Benefits NewsLife Insurance News
- Navigating delayed death certificates: A guide for life insurance advisors
- Jackson Launches Direct-to-Consumer Annuity Offering
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on New Zealand’s Non-Life Insurance Segment
- AM Best Affirms Credit Ratings of Fubon Insurance Vietnam Co., Ltd.
- Three lawsuits put life insurers’ cost-of-insurance practices under scrutiny
More Life Insurance News